1. Search Result
Search Result
Results for "

Antileukemic.

" in MedChemExpress (MCE) Product Catalog:

128

Inhibitors & Agonists

4

Inhibitory Antibodies

32

Natural
Products

15

Isotope-Labeled Compounds

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13677
    6-Mercaptopurine
    Maximum Cited Publications
    17 Publications Verification

    Mercaptopurine; 6-MP

    Nucleoside Antimetabolite/Analog Autophagy Endogenous Metabolite Cancer
    6-Mercaptopurine is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive drug.
    6-Mercaptopurine
  • HY-17381
    Idarubicin hydrochloride
    Maximum Cited Publications
    17 Publications Verification

    4-Demethoxydaunorubicin hydrochloride

    Topoisomerase Bacterial Fungal Autophagy Antibiotic DNA/RNA Synthesis c-Myc Infection Cancer
    Idarubicin hydrochloride is an anthracycline antileukemic agent. It inhibits the topoisomerase II interfering with the replication of DNA and RNA transcription. Idarubicin hydrochloride inhibits the growth of bacteria and yeasts.
    Idarubicin hydrochloride
  • HY-153274
    CWI1-2
    4 Publications Verification

    Apoptosis Cancer
    CWI1-2 is an IGF2BP2 inhibitor that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, induces apoptosis and differentiation, and shows promising anti-leukemic effects .
    CWI1-2
  • HY-112885B
    nor-NOHA monoacetate
    5 Publications Verification

    Nω-Hydroxy-nor-L-arginine monoacetate

    Arginase Apoptosis Cardiovascular Disease Infection Metabolic Disease Inflammation/Immunology Cancer
    nor-NOHA monoacetate is a selective and reversible arginase inhibitor. nor-NOHA monoacetate induces apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA monoacetate has anti-leukemic activity. nor-NOHA monoacetate can used in study of endothelial dysfunction, immunosuppression and metabolism .
    nor-NOHA monoacetate
  • HY-P99412
    Lusvertikimab
    1 Publications Verification

    OSE-127

    Interleukin Related Cancer
    Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research .
    Lusvertikimab
  • HY-100423
    Eltanexor
    3 Publications Verification

    KPT-8602

    CRM1 Cancer
    Eltanexor (KPT-8602) is a second-generation, highly specific and orally active exportin-1 (XPO1) inhibitor with potent anti-leukemic activity. Eltanexor (KPT-8602) inhibits XPO1-dependent nuclear export (EC50=60.9 nM) by directly targeting XPO1. Eltanexor (KPT-8602) induces Caspase-dependent apoptosis in a panel of leukemic cell lines .
    Eltanexor
  • HY-17381A
    Idarubicin
    Maximum Cited Publications
    17 Publications Verification

    4-Demethoxydaunorubicin

    Topoisomerase Bacterial Fungal Autophagy c-Myc DNA/RNA Synthesis Antibiotic Infection Cancer
    Idarubicin is an orally active and potent anthracycline antileukemic agent. Idarubicin inhibits the topoisomerase II interfering with the replication of DNA and RNA transcription. Idarubicin shows induction of DNA damage. Idarubicin inhibits DNA synthesis and of c-myc expression. Idarubicin inhibits the growth of bacteria and yeasts .
    Idarubicin
  • HY-X0009
    Tambiciclib
    1 Publications Verification

    GFH009; JSH-009; SLS009

    CDK DYRK Apoptosis Bcl-2 Family c-Myc Caspase PARP DNA/RNA Synthesis Metabolic Disease Inflammation/Immunology Cancer
    Tambiciclib (GFH009, JSH-009) is an orally active, highly potent and selective CDK9 inhibitor (IC50 = 1 nM), demonstrating >200-fold selectivity over other CDKs, >100-fold selectivity over DYRK1A/B, and excellent selectivity over 468 kinases/mutants. Tambiciclib demonstrates potent in vitro and in vivo antileukemic efficacy in acute myeloid leukemia (AML) mouse models by inhibiting RNA Pol II phosphorylation, downregulating MCL1 and MYC, and inducing apoptosis. Tambiciclib can be used for AML research .
    Tambiciclib
  • HY-123954
    BTX-A51
    1 Publications Verification

    Casein Kinase inhibitor A51

    Casein Kinase CDK Apoptosis Cancer
    BTX-A51 (Casein Kinase inhibitor A51) is a potent and orally active casein kinase 1α (CK1α) inhibitor. BTX-A51 induces leukemia cell apoptosis, and has potent anti-leukemic activities .
    BTX-A51
  • HY-B1516
    Alovudine
    3 Publications Verification

    3'-Fluoro-3'-deoxythymidine; 3′-Deoxy-3′-fluorothymidine; FLT

    DNA/RNA Synthesis Orthopoxvirus Infection Cancer
    Alovudine (3'-Fluoro-3'-deoxythymidine) is a mtDNA synthesis inhibitor and a marker of DNA synthesis. Alovudine is less susceptible to inflammatory changes than 18F-Fluorodeoxyglucose (FDG) and thus is a better biomarker in pancreatic cancer. Alovudine shows anti-orthopoxvirus and anti-leukemic activity .
    Alovudine
  • HY-112885A
    nor-NOHA acetate
    5 Publications Verification

    Nω-Hydroxy-nor-L-arginine acetate

    Arginase Apoptosis Cardiovascular Disease Infection Metabolic Disease Inflammation/Immunology Cancer
    nor-NOHA acetate is a selective and reversible Arginase inhibitor. nor-NOHA acetate induces Apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA acetate has anti-leukemic activity. nor-NOHA acetate improves liver ischemia-reperfusion injury. nor-NOHA acetate can used in study of tuberculosis, endothelial dysfunction, immunosuppression and metabolism .
    nor-NOHA acetate
  • HY-109117
    Iadademstat
    5+ Cited Publications

    ORY-1001

    Histone Demethylase Apoptosis Cancer
    Iadademstat (ORY-1001) is a highly potent, orally active and selective LSD1 (KDM1A) inhibitor with antileukemic activity. Iadademstat can be used for relapsed or refractory acute myeloid leukemia research .
    Iadademstat
  • HY-112885C
    nor-NOHA dihydrochloride
    5 Publications Verification

    Nω-Hydroxy-nor-L-arginine dihydrochloride

    Apoptosis Arginase Cardiovascular Disease Infection Metabolic Disease Inflammation/Immunology Cancer
    nor-NOHA dihydrochloride is a selective and reversible Arginase inhibitor. nor-NOHA dihydrochloride induces Apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA dihydrochloride has anti-leukemic activity. nor-NOHA dihydrochloride improves liver ischemia-reperfusion injury. nor-NOHA dihydrochloride can used in study of tuberculosis, endothelial dysfunction, immunosuppression and metabolism .
    nor-NOHA dihydrochloride
  • HY-13677A
    6-Mercaptopurine hydrate
    Maximum Cited Publications
    17 Publications Verification

    Mercaptopurine hydrate; 6-MP hydrate

    Nucleoside Antimetabolite/Analog Cancer
    6-Mercaptopurine hydrate (Mercaptopurine hydrate; 6-MP hydrate) is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive agent.
    6-Mercaptopurine hydrate
  • HY-135231
    NL-1
    5 Publications Verification

    Mitochondrial Metabolism Autophagy Cancer
    NL-1 is a mitoNEET inhibitor with antileukemic effect. NL-1 inhibits REH and REH/Ara-C cells growth with IC50s of 47.35 μM and 56.26 μM, respectively. NL-1-mediated death in leukemic cells requires the activation of the autophagic pathway .
    NL-1
  • HY-112041
    Unesbulin
    3 Publications Verification

    PTC596

    BMI1 Apoptosis Cancer
    Unesbulin (PTC596) is an orally active and selective B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) inhibitor. Unesbulin downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia (AML) cells. Unesbulin has anti-leukemic activity .
    Unesbulin
  • HY-135190
    (-)-Cedrene
    2 Publications Verification

    α-cedrene

    Environmental Pollutants Bacterial Infection Metabolic Disease Cancer
    (-)-Cedrene (α-cedrene) is a major constituent that can be found in essential oils. (-)-Cedrene (α-cedrene) is a natural, orally active ligand of mouse olfactory receptor 23, which induces skeletal muscle hypertrophy in mice. (-)-Cedrene exhibits trypanocidal (Trypanosoma b. brucei) (IC50 = 4.07 μg/mL). (-)-Cedrene is antileukemic in vitro (IC50 = 22.2 μg/mL). (-)-Cedrene has antimicrobial activity against anaerobic bacteria and yeast. (-)-Cedrene exhibits anti-obesity activity .
    (-)-Cedrene
  • HY-N0838
    Cephalotaxine
    1 Publications Verification

    (-)-Cephalotaxine; ZINC19795976

    Flavivirus Infection Cancer
    Cephalotaxlen ((-)-Cephalotaxine) is an alkaloid that can be isolated from Cephalotaxus fortunei, with antileukemic and antiviral activities. Cephalotaxlen has anti-ZIKV (Zika virus) activity .
    Cephalotaxine
  • HY-102048
    STAT5-IN-2
    2 Publications Verification

    STAT Apoptosis Cancer
    STAT5-IN-2 is a STAT5 inhibitor, extracted from reference 1, example 17f. STAT5-IN-2 has potent antileukemic effect .
    STAT5-IN-2
  • HY-153274A
    CWI1-2 hydrochloride
    4 Publications Verification

    Apoptosis Cancer
    CWI1-2 hydrochloride is an IGF2BP2 inhibitor that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, induces apoptosis and differentiation, and shows promising anti-leukemic effects .
    CWI1-2 hydrochloride
  • HY-141429A
    AS-99 TFA
    2 Publications Verification

    Histone Methyltransferase Apoptosis Cancer
    AS-99 TFA is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC50= 0.79 μM, Kd= 0.89 μM) with anti-leukemic activity. AS-99 TFA blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo .
    AS-99 TFA
  • HY-B1336
    Furazolidone
    3 Publications Verification

    Environmental Pollutants Antibiotic Bacterial Apoptosis Parasite Infection Cancer
    Furazolidone is a monoamine oxidase (MAO) inhibitor with antiproliferative, apoptosis-inducing and differentiation-promoting activities. Furazolidone may inhibit leukemia fusion protein-mediated bone marrow transformation by upregulating the stability of the tumor suppressor protein p53. Furazolidone exhibits anti-leukemic activity in acute myeloid leukemia (AML) cell lines and can be used for anti-AML research [2].
    Furazolidone
  • HY-112885

    Nω-Hydroxy-nor-L-arginine

    Apoptosis Arginase Cardiovascular Disease Infection Metabolic Disease Inflammation/Immunology Cancer
    nor-NOHA is a selective and reversible arginase inhibitor. nor-NOHA induces apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA has anti-leukemic activity. nor-NOHA can used in study of endothelial dysfunction, immunosuppression and metabolism .
    nor-NOHA
  • HY-169091

    DNA/RNA Synthesis Cancer
    TS-002266 is a small molecule TUT4/7 inhibitor with anti-leukemic effects. TS-002266 is promising for research of cancers .
    TS-002266
  • HY-117996

    CRM1 Apoptosis Cancer
    KPT-251 is an orally active chromosome region maintenance 1 protein (CRM1) inhibitor. KPT-251 induces cancer cell apoptosis and shows antileukemic activity .
    KPT-251
  • HY-109179

    TP-0184

    JAK Anaplastic lymphoma kinase (ALK) FLT3 STAT PI3K Akt mTOR TGF-beta/Smad TGF-β Receptor Cancer
    Itacnosertib (TP-0184) is the inhibitor for FLT3, ACVR1 (ALK2, IC50=8 nM) and JAK2 (IC50=8540 nM). Itacnosertib exhibits anti-leukemic activity .
    Itacnosertib
  • HY-149334

    Fat Mass and Obesity-associated Protein (FTO) Metabolic Disease
    ZLD115 (compound 44) is a FB23-derivated inhibitor of Fat Mass and Obesity-associated Protein (FTO). ZLD115 is an antileukemic agent, exhibiting antiproliferative activity against leukemic cell lines .
    ZLD115
  • HY-15003

    FLT3 Apoptosis Cancer
    ATH686 is a potent, selective and ATP-competitive FLT3 inhibitor. ATH686 target mutant FLT3 protein kinase activity and inhibit the proliferation of cells harboring FLT3 mutants via induction of apoptosis and cell cycle inhibition. ATH686 has antileukemic effects .
    ATH686
  • HY-123955

    Casein Kinase CDK Apoptosis Cancer
    Casein Kinase inhibitor A86 is a potent and orally active casein kinase 1α (CK1α) inhibitor. Casein Kinase inhibitor A86 also inhibits of CDK7 (TFIIH) and CDK9 (P-TEFb). Casein Kinase inhibitor A861 induces leukemia cell apoptosis, and has potent anti-leukemic activities .
    Casein Kinase inhibitor A86
  • HY-134978B

    SHMT Cancer
    (-)SHIN2 is the isomer of (+)SHIN2 (HY-134978A). (+)SHIN2 is an inhibitor of serine hydroxymethyltransferase (SHMT) with antileukemic effect. (+)SHIN2 synergisty with and Methotrexate (HY-14519) in vivo xenotransplantation models . (-)SHIN2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    (-)SHIN2
  • HY-123523

    Nucleoside Antimetabolite/Analog DNA/RNA Synthesis CMV Infection Cancer
    Enocitabine is a nucleoside analog, and is a potent DNA replication inhibitor, and a DNA chain terminator. Enocitabine inhibits the replication of human cytomegalovirus. Enocitabine has antileukemic and antiviral activities .
    Enocitabine
  • HY-141430

    Histone Methyltransferase Cancer
    AS-85 is a potent ASH1L histone methyltransferase inhibitor (IC50=0.6 μM) with anti-leukemic activity. AS-85 strongly binds to the ASH1L SET domain, with the Kd value of 0.78 μM .
    AS-85
  • HY-122295

    Apoptosis Inflammation/Immunology Cancer
    Dehydroleucodine is a sesquiterpene lactone isolated from Artemisia douglasiana. Dehydroleucodine is a mast cell stabilizer that inhibits tmast cell degranulation induced by compound 48/80. Dehydroleucodine inudces cells apoptosis, and has gastric ulcer inhibition and antileukemic effects .
    Dehydroleucodine
  • HY-13677S1

    Mercaptopurine-13C2,15N; 6-MP-13C2,15N

    Nucleoside Antimetabolite/Analog Autophagy Endogenous Metabolite Cancer
    6-Mercaptopurine- 13C2, 15N is the 13C- and 15N-labeled 6-Mercaptopurine. 6-Mercaptopurine is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive agent.
    6-Mercaptopurine-13C2,15N
  • HY-134333

    Apoptosis Cancer
    ICCB280 is a potent inducer of C/EBPα. ICCB280 exhibits anti-leukemic properties including terminal differentiation, proliferation arrest, and apoptosis through activation of C/EBPα and affecting its downstream targets (such as C/EBPε, G-CSFR and c-Myc) .
    ICCB280
  • HY-153495

    BP1001

    Bcl-2 Family Apoptosis Reactive Oxygen Species (ROS) Cancer
    Prexigebersen (BP1001) is an antisense oligonucleotide targeting Bcl-2 and Grb2. Prexigebersen exhibits antileukemic activity in cell models. Prexigebersen induces apoptosis (apoptosis), cell cycle arrest and ROS production in leukemia cells. Prexigebersen inhibits Grb2 expression, thereby suppressing tumor growth and survival. Prexigebersen can be used in studies related to acute myeloid leukemia .
    Prexigebersen
  • HY-109179A

    TP-0184 hydrochloride

    JAK Anaplastic lymphoma kinase (ALK) FLT3 STAT PI3K Akt mTOR TGF-beta/Smad TGF-β Receptor Cancer
    Itacnosertib hydrochloride (TP-0184 hydrochloride) is the inhibitor for FLT3, ACVR1 (ALK2, IC50=8 nM) and JAK2 (IC50=8540 nM). Itacnosertib hydrochloride exhibits anti-leukemic activity .
    Itacnosertib hydrochloride
  • HY-13677AR

    Mercaptopurine hydrate (Standard); 6-MP hydrate (Standard)

    Reference Standards Nucleoside Antimetabolite/Analog Cancer
    6-Mercaptopurine hydrate (Standard) is the analytical standard of 6-Mercaptopurine hydrate. This product is intended for research and analytical applications. 6-Mercaptopurine hydrate (Mercaptopurine hydrate; 6-MP hydrate) is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive agent.
    6-Mercaptopurine hydrate (Standard)
  • HY-141429
    AS-99 free base
    2 Publications Verification

    Histone Methyltransferase Apoptosis Cancer
    AS-99 is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC50= 0.79 µM, Kd= 0.89 µM) with anti-leukemic activity. AS-99 blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo .
    AS-99 free base
  • HY-120997

    Berbamine p-nitrobenzoate

    Calmodulin Myosin Phosphodiesterase (PDE) Cardiovascular Disease Cancer
    E6 Berbamine (Berbamine p-nitrobenzoate) is a potent calmodulin (CaM) antagonist. E6 Berbamine inhibits the activities of calmodulin-dependent myosin light chain kinase (MLCK) and phosphodiesterase (PDE). E6 Berbamine exhibits anti-leukemic activity. E6 Berbamine can be used in research related to cardiovascular abnormalities and chronic myeloid leukemia .
    E6 Berbamine
  • HY-150109A

    HDAC Cancer
    Purinostat is a selective inhibitor of HDAC I/IIb with anti-leukemic activity. Purinostat mesylate (HY-150109), the mesylate salt of Purinostat, inhibits the survival of Ph+ leukemic cells and CD34+ leukemic cells derived from CML patients. Purinostat mesylate targets HDAC I/IIb to inhibit several important factors for leukemic stem cell (LSC) survival, including c-Myc, β-Catenin, E2f, Ezh2, Alox5, and mTOR. Purinostat mesylate increases glutamate metabolism in LSC by increasing GLS1 .
    Purinostat
  • HY-P99027

    LAG525; IMP701; Hu5A8

    LAG-3 Cancer
    Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors .
    Ieramilimab
  • HY-133900

    Others Cancer
    Deoxyharringtonine is an alkaloid isolated from Cephalotaxus genus with significant anti-leukemic activity .
    Deoxyharringtonine
  • HY-U00095
    Hepsulfam
    2 Publications Verification

    NCI 329680; ZINC01574758

    DNA Alkylator/Crosslinker Cancer
    Hepsulfam (NCI 329680; ZINC01574758) is a anticancer agent that shows excellent antileukemic activity with an median IC50 of 0.91 μg/mL in a panel of different tumors.
    Hepsulfam
  • HY-111008A

    VF-233 hydrochloride

    DNA/RNA Synthesis Cancer
    Trimidox hydrochloride (VF-233) is a ribonucleotide reductase inhibitor with antileukemic activities. Trimidox hydrochloride inhibits the growth of human promyelocytic leukemia HL-60 cells with an IC50 of 35 μM .
    Trimidox hydrochloride
  • HY-13677S

    Mercaptopurine-d2; 6-MP-d2

    Isotope-Labeled Compounds Nucleoside Antimetabolite/Analog Autophagy Endogenous Metabolite Cancer
    6-Mercaptopurine-d2 is the deuterium labeled 6-Mercaptopurine. 6-Mercaptopurine is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive agent .
    6-Mercaptopurine-d2
  • HY-111275

    JAK STAT Apoptosis Caspase PARP Cancer
    WP-1034 is a JAK-STAT inhibitor with proapoptotic and antileukemic activity in acute myeloid leukemia (AML). WP-1034 blocks activation of Stat 3 and 5. WP-1034 induces cell cycle arrest and triggers apoptosis. WP-1034 can be used for AML research .
    WP-1034
  • HY-157327

    Bcr-Abl Cancer
    AKE-72 (compound 5) is a potent inhibitor of Pan-BCR-ABL. AKE-72 inhibits BCR-ABL WT, BCR-ABL T315, BCR-ABL E255K, BCR-ABL F3171, BCR-ABL H396P and BCR-ABL Q252H with IC50s of < 0.5, 9, 8.98, 3.12, < 1.0 and 3.88 nM, respectively. AKE-72 has anti-leukemic activity against K-562 cell line .
    AKE-72
  • HY-U00095R

    NCI 329680 (Standard); ZINC01574758 (Standard)

    DNA Alkylator/Crosslinker Reference Standards Cancer
    Hepsulfam (NCI 329680; ZINC01574758) is a anticancer agent that shows excellent antileukemic activity with an median IC50 of 0.91 μg/mL in a panel of different tumors.
    Hepsulfam (Standard)
  • HY-17381R

    4-Demethoxydaunorubicin hydrochloride (Standard)

    Reference Standards Topoisomerase Bacterial Fungal Autophagy Antibiotic DNA/RNA Synthesis c-Myc Infection Cancer
    Idarubicin (hydrochloride) (Standard) is the analytical standard of Idarubicin (hydrochloride). This product is intended for research and analytical applications. Idarubicin hydrochloride is an anthracycline antileukemic agent. It inhibits the topoisomerase II interfering with the replication of DNA and RNA transcription. Idarubicin hydrochloride inhibits the growth of bacteria and yeasts.
    Idarubicin hydrochloride (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: